Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 2020;396(10254):839 – 52

Abramson JS, Palomba ML, Gordon LI, et al. Two-year follow-up of TRANSCEND NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphomas. Blood 2021;138(Supplement 1):2840

Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403(6769):503 – 11

Amini L, Silbert SK, Maude SL, et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol 2022;19(5):342 – 55

Arcangeli S, Falcone L, Camisa B, et al. Next-generation manufacturing protocols enriching TSCM CAR T cells can overcome disease-specific T cell defects in cancer patients. Front Immunol 2020;11:1217

Bachier CR, Godwin JE, Andreadis C, et al. Outpatient treatment with lisocabtagene maraleucel (liso-cel) across a variety of clinical sites from three ongoing clinical studies in relapsed/refractory (R/R) large B-cell lymphoma (LBCL). J Clin Oncol 2020;38(15_suppl):8037

Bethge WA, Martus P, Schmitt M, et al. Standard of care CAR-T cell therapy for large B-cell lymphoma: does bridging efficacy matter? A german GLA/DRST real world analysis. Blood 2021;138(Supplement 1):3822

Bethge WA, Martus P, Schmitt M, et al. GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. Blood 2022; 10.1182/blood.2021015209

Borogovac A, Keruakous A, Bycko M, et al. Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center. Bone Marrow Transplant 2022;57(6):1025 – 7

Brücklein VL, Bader P, Bargou RC, et al. CAR-T Zellen: Management von Nebenwirkungen. Onkopedia Leitlinie. DGHO. 2020. https://www.onkopedia.com/ de/onkopedia/guidelines/car-t-zellen-management-von-nebenwirkungen/@@guideline/html/index.html, abgerufen am: 22.01.2021

Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev 2019;34:45 – 55

Cahill KE, Leukam MJ, Riedell PA. Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma. Leuk Lymphoma 2020;61(4):799 – 807

Cappell KM, Kochenderfer JN. A comparison of chimeric antigen receptors containing CD28 versus 41BB costimulatory domains. Nat Rev Clin Oncol 2021;18(11):715 – 27

Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 2018;24(5):679 – 90

Chong EA, Melenhorst JJ, Lacey SF, et al. PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR. Blood 2017;129(8):1039 – 41

Cordeiro A, Bezerra ED, Hirayama AV, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transplant 2020;26(1):26 – 33

Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 2014;32(31):3490 – 6

Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017;130(16):1800 – 8

Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013;381(9880):1817 – 26

Dholaria BR, Bachmeier CA, Locke F. Mechanisms and management of chimeric antigen receptor T-cell therapy-related toxicities. BioDrugs 2019;33(1):45 – 60

Duell J, Maddocks KJ, Gonzalez-Barca E, et al. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica 2021;106(9):2417 – 26

EC. Yescarta ® : Zusammenfassung der Merkmale des Arzneimittels. 2022. https://ec.europa.eu/health/documents/community-register/html/h1299.htm, abgerufen am: 02.11.2022

El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 2007;18(8):1363 – 8

EMA. Minjuvi ® : Zusammenfassung der Merkmale des Arzneimittels. 2022a. https://www.ema.europa.eu/documents/product-information/minjuvi-epar- product-information_de.pdf, abgerufen am: 24.08.2022

EMA. Zynlonta ® : Opinion. 2022b. https://www.ema.europa.eu/en/medicines/human/summaries-opinion/zynlonta, abgerufen am: 02.11.2022

Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993;90(2):720 – 4

Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 2004;172(1):104 – 13

Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28(27):4184 – 90

Holzinger A, Abken H. Chimäre Antigenrezeptoren (CAR) – universelle Werkzeuge in der zellulären Immuntherapie. Der Internist 2021;62(6):583 – 8

International Non-Hodgkin‘s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin‘s lymphoma. N Engl J Med 1993;329(14):987 – 94

Jacobson C, Locke FL, Ghobadi A, et al. Long-term overall survival by 12- and 24-month event-free survival: an updated analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel in patients with refractory large B-Cell lymphoma. Blood 2021;138(Supplement 1):1764

Jain MD, Zhao H, Wang X, et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood 2021a;137(19):2621 – 33

Jain MD, Ziccheddu B, Coughlin CA, et al. Genomic drivers of large B-cell lymphoma resistance to CD19 CAR-T therapy. Blood 2021b;138(Supplement 1):42

Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophos- phamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30(28):3452 – 9

Klapper W, Fend F, Feller A, et al. Aggressive B-Zell-Lymphome. Der Pathologe 2019;40(2):152 – 6

Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effec- tor cells. Biol Blood Marrow Transplant 2019;25(4):625 – 38

Lenz G. Onkopedia Leitlinie – Diffuses großzelliges B-Zell-Lymphom. 2022. https://www.onkopedia.com/de/onkopedia/guidelines/diffuses-grosszelliges- b-zell-lymphom/@@guideline/html/index.html#litID0EEVAE, abgerufen am: 17.07.2022

Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin‘s disease: Cots- wolds meeting. J Clin Oncol 1989;7(11):1630 – 6

LMU Klinikum München. Pressemitteilung: Erste ambulante CAR-T-Zell-Therapie. 2021. https://www.lmu-klinikum.de/aktuelles/pressemitteilungen/erste- ambulante-car-t-zell-therapie/40ced104ee27e212, abgerufen am: 11.05.2022

Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single- arm, multicentre, phase 1 – 2 trial. Lancet Oncol 2019;20(1):31 – 42

Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386(7):640 – 54

Long AH, Haso WM, Shern JF, et al. 41BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 2015;21(6):581 – 90

Lu P, Hill HA, Navsaria LJ, et al. CAR-T and other adoptive cell therapies for B cell malignancies. Journal of the National Cancer Center 2021;1(3):88 – 96

Majzner RG, Rietberg SP, Sotillo E, et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov 2020;10(5):702 – 23

Meng J, Wu X, Sun Z, et al. Efficacy and safety of CAR-T cell products axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel for the treat - ment of hematologic malignancies: a systematic review and meta-analysis. Front Oncol 2021;11:698607

Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992 – 2001. Blood 2006;107(1):265 – 76

Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: Results from the US Lym- phoma CAR T consortium. J Clin Oncol 2020;38(27):3119 – 28

NCT03391466. Efficacy of axicabtagene ciloleucel compared to standard of care therapy in subjects with relapsed/refractory diffuse large B cell lymphoma (ZUMA-7). https://clinicaltrials.gov/ct2/show/NCT03391466, abgerufen am: 30.09.2022

NCT03570892. Tisagenlecleucel in adult patients with aggressive B-cell Non-Hodgkin lymphoma (BELINDA). https://clinicaltrials.gov/ct2/show/NCT03570892, abgerufen am: 30.09.2022

NCT03575351. A study to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive B-cell Non-Hodgkin lymphomas (TRANSFORM). https://clinicaltrials.gov/ct2/show/NCT03575351, abgerufen am: 30.09.2022

NCT03589469. Study to evaluate the efficacy and safety of loncastuximab tesirine in patients with relapsed or refractory diffuse large B-cell lymphoma (LOTIS- 2). https://clinicaltrials.gov/ct2/show/NCT03589469, abgerufen am: 02.11.2022

NCT03761056. Study to evaluate the efficacy and safety of axicabtagene ciloleucel as first-line therapy in participants with high-risk large B-cell lymphoma (ZUMA-12). https://clinicaltrials.gov/ct2/show/NCT03761056, abgerufen am: 30.09.2022

Neelapu SS, Dickinson M, Munoz J, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med 2022;28(4):735 – 42

Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377(26):2531 – 44

Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. Nat Rev Clin Oncol 2018;15(1):47 – 62

Oluwole OO, Jansen JP, Lin VW, et al. Comparing efficacy, safety, and preinfusion period of axicabtagene ciloleucel versus tisagenlecleucel in relapsed/ refractory large B cell lymphoma. Biol Blood Marrow Transplant 2020;26(9):1581 – 8

Pfreundschuh M, Kuhnt E, Trümper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011;12(11):1013 – 22

Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9(2):105 – 16

Rabinovich E, Pradhan K, Sica RA, et al. Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort. Exp Hematol Oncol 2021;10(1):55

Read JA, Koff JL, Nastoupil LJ, et al. Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms. Clin Lymphoma Myeloma Leuk 2014;14(6):460 – 7

Recher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03 – 2B): an open-label randomised phase 3 trial. Lancet 2011;378(9806):1858 – 67

Rejeski K, Perez A, Sesques P, et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood 2021;138(24):2499 – 513

Rosenwald A, Bens S, Advani R, et al. Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker consortium. J Clin Oncol 2019;37(35):3359 – 68

Schmitz N, Nickelsen M, Ziepert M, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002 – 1). Lancet Oncol 2012;13(12):1250 – 9

Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 2018;378(15):1396 – 407

Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019;380(1):45 – 56

Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lympho- mas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021;22(10):1403 – 15

Scott DW, King RL, Staiger AM, et al. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood 2018;131(18):2060 – 4

Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38(2):155 – 65

Sim AJ, Jain MD, Figura NB, et al. Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma. Int J Radiat Oncol Biol Phys 2019;105(5):1012 – 21

Sommermeyer D, Hudecek M, Kosasih PL, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 2016;30(2):492 – 500

Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, 4. Auflage. International Agency for Research on Cancer, Lyon, 2017

Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2021;386(4):351 – 63

Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002;2(10):735 – 47

Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin‘s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med 2016;8(355):355ra116

van Imhoff GW, McMillan A, Matasar MJ, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: The ORCHARRD study. J Clin Oncol 2017;35(5):544 – 51

Voorhees TJ, Zhao B, Oldan J, et al. Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma. Blood Adv 2022;6(4):1255 – 63

Westin JR, Kersten MJ, Salles G, et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol 2021;96(10):1295 – 312

Yan Z, Zhang H, Cao J, et al. Characteristics and risk factors of cytokine release syndrome in chimeric antigen receptor T cell treatment. Front Immunol 2021;12:611366

Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28(14):2373 – 80

Zola H, MacArdle PJ, Bradford T, et al. Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol Cell Biol 1991;69 ( Pt 6)(6):411 – 22